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The global healthcare industry is undergoing substantial changes and adaptations to the constant decline of
approved new medical entities. This decrease in internal research productivity is resulting in a major decline of
patent-protected sales (patent cliff) of most of the pharmaceutical companies. Three major global adaptive trends
as driving forces to cope with these challenges are evident: cut backs of internal research and development jobs in
the western hemisphere (Europe and USA), following the market growth potential of Asia by building up internal or
external research and development capabilities there and finally, ‘early innovation hunting’ with an increased focus
on identifying and investing in very early innovation sources within academia and small start-up companies. Early
innovation hunting can be done by different approaches: increased corporate funding, establishment of
translational institutions to bridge innovation, increasing sponsored collaborations and formation of technology
hunting groups for capturing very early scientific ideas and concepts. This emerging trend towards early innovation
hunting demands special adaptations from both the pharmaceutical industry and basic researchers in academia to
bridge the translation into new medicines which deliver innovative medicines that matters to the patient. This
opinion article describes the different modalities of cross-fertilisation between basic university or publicly funded
institutional research and the applied research and development activities within the pharmaceutical industry. Two
key factors in this important translational bridge can be identified: preparation of both partnering organisations to
open up for new and sometime disruptive ideas and creation of truly trust-based relationships between the
different groups allowing long-term scientific collaborations while acknowledging that value-creating differences
are an essential factor for successful collaboration building.
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The human population is facing substantial challenges in
the next coming decades with respect to their healthcare:
We see an increasing size of the ageing populations, espe-
cially in the industrial countries like North America,
Europe and Japan. On the other side, there is a clear ‘glo-
balisation’ of healthcare accompanied by an increasing
need for improved medication in developing countries. In
addition, the constantly increasing costs for the healthcare
system leads to a focus towards ‘precise’ medicines. These
medicines must have a better therapeutic window, should* Correspondence: Paul-Georg.Germann@takeda.com
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reproduction in any medium, provided the orbe personalised to patients needs and accompanied by a
validated biomarker concept and might even be combined
with other medicines. Therefore, the scope of new re-
search activities in the healthcare system is even broad-
ened by the need to address potentially unfamiliar and
complex diseases, new modes of action and challenges like
smaller but more distinct multiple patient populations.
New therapies will combine pharmaceuticals, diagnostics
and devices, with an increase reporting and monitoring of
effects via an enhanced IT environment. An increase in
innovation is one answer to the upcoming challenges just
mentioned. Here, it is important to note that the majority
of innovation occurs outside of the pharmaceutical indus-
try. With these upcoming challenges in mind, the globalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adaptations to the constant decline of approved new med-
ical entities (see Figure 1) [1-3].
This decrease in the internal research productivity
within most of the larger pharmaceutical companies will
prospectively result in a major decline of patent-protected
sales (so called ‘patent cliff ’) of most of the pharmaceutical
companies.
Three major global adaptive trends as driving forces
are evident:
1. Cut backs of internal research and development jobs
in the western hemisphere (Europe and USA, see
Table 1),
2. Following the market growth potential of Asia by
building up internal or external research and
development capabilities there and
3. ‘Early innovation hunting’ with an opening of the
pharmaceutical companies towards very early
innovation sources within academia and small start-
up companies. This can be done by different means:
increased corporate funding, translational institutions
to bridge innovation, increasing sponsored
collaborations and technology hunting groups for
front leading very early scientific ideas and concepts.
Especially, this trend of early innovation hunting de-
mands special adaptations not only from pharmaceutical
industry, but also from basic research in academia toFigure 1 FDA drug approvals.bridge the translation into new medicines which matters
to the patient.
On the other side of this innovation bridge, the univer-
sities and research institutions will see a static or even a
decline in governmental funding, while corporate ven-
ture funding takes an increasing stake of importance in
the financial system of these research institutions. Cor-
porations are increasingly investing into healthcare as
shown in Figure 2.
Main text
This opinion article describes the different modalities of
cross-fertilisation between basic university or publicly
funded research institutions and the applied research
and development activities within the pharmaceutical in-
dustry. Some key phases in this important translational
bridge can be identified:
1. Prepare the organisations on both sides for opening
up for new ideas
2. Find the opportunities and open the doors to
innovation
3. Create trust within the scientific collaboration
4.Develop and select the winning project as a team
5. Translate the innovation into the value chain of a big
pharmaceutical company
Prepare the organisations
The need for a substantial increase of innovative ideas in
the health care sector has led to a higher awareness and a
Table 1 Cut backs of internal research and development
jobs in the western hemisphere (Europe and USA),
September 2012







2,000 US sales jobs
2 Sanofi Imminent Reportedly up to 2,000
French jobs
3 Pfizer 2005 Still another 12,100 of
planned 60,000 jobs to be
cut
4 Roche June 2012 Nutley site to close, 1,000 R
and D jobs
5 GlaxoSmithKline NA Ongoing restructuring, no
specific job target
announced
6 Merck & Co July 2011 12% to13% workforce















NA Ongoing, 295 jobs cut so far
in 2012
10 AstraZeneca Feb 2012 7,300 jobs, including 2,200 in
R and D
NA not applicable, R and D research and development. Source: Takeda Media
Monitoring 19 September 2012.
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pharmaceutical industry. The universities/institutions with
their technology transfer offices (TTO) are working here as
change agents in two directions: by exposing the academics
towards external interested partners via ‘open research days’
and business development conferences and by using
their manifold networks outside the universities; a mindset
change towards a customer orientation is the ultimate goal.
In the external direction, fostering of their relationships to
newly interested partners is an attempt to seek attention of
potential new collaborations and ultimately, funding and
partners for the research assets. A challenging point here is
the current focus of many TTO and pharmaceutical com-
panies on developed projects with the aim to generate on a
fast track mode intellectual property (IP) and a licence op-
tion to be granted. Very embryonic assets are normally not
in the focus of these kinds of TTO activities.
The hunting and scouting groups of pharmaceutical
companies have the critical task to prepare the internal
organisation for additional projects to supplement a
much-focused high project load of the internal discov-
ery, development and project management organisation.An environment in which external ideas are viewed as
threatening competitors to internal project resources
needs to be changed by constant communication flow
into an open-minded welcoming spirit, which sees the
new ideas coming from external as a critical success fac-
tor for the whole company. The term ‘landing path’
pictures well this attempt to prepare the internal pharma-
ceutical company organisation as an open, embracing and
welcoming path towards external innovation.
Find the opportunities and open the doors
Innovation is available in all academic institutions all over
the world. Comparing the total sizes of organisations and
the total budget spent, academic institutions are outpacing
the capacities of the pharmaceutical industry by far. Find-
ing the ‘right’ innovation opportunities, which suits the
company’s needs, should use strategic competitive inte-
lligence approaches in a smart and efficient way. The term
‘right opportunity’ will be addressed later. A good general
overview of the academic landscape with respect to grant,
publication and technology and therapeutic field ranking
is the basis. A broad personal network of the company
scientists within the selected scientific community is the
second important factor to access scientific partners.
Thirdly, the building of personal relationships between
company and key academic scientists of the selected hot
spots of interests are an important factor, which might
help to open the right door to the right innovation.
To create trust within the scientific collaboration is the
key factor of creating a joined success story between aca-
demic and pharmaceutical scientists. First of all, in the
first introductory meetings, the innovative idea needs to
be fully understood by both sides. This means that the col-
leagues from the pharmaceutical industry have to generate
a deep insight into the basic biology or technology to get
accepted by the academic collaborator. On the other side,
their project and development knowledge and the stra-
tegic health benefit perspective, which they bring to the
table, might be very beneficial for the academic side as an
eye-opener. This kind of relationship building might take
several meetings where ongoing discussions might shape
more and more the possible joint project. In addition, the
pharmaceutical company as a partner can support the aca-
demic innovator by giving him/her access to the company
compound libraries and connect them to specialised ex-
perts and additional technologies. Especially in the case of
very early innovative ideas, this phase is a very important
process of relationship building as the ‘way forward to-
wards a medicine that matters’ is often not evident and
straightforward.
Develop and select the winning project as a team
During the idea-shaping discussions, the development and
translational project knowledge of the pharmaceutical
Figure 2 Trends in innovation funding: a US perspective.
Figure 3 Important deliverables and dependencies in innovation management.
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Figure 4 Strategic elements in innovation management.
Table 2 Soft skill set of innovation hunters
● Active search for innovative solutions to disease
● Articulate the disease or therapeutic area challenge
● Radars a range of innovative technologies and solutions
● Bridges a range risk and time spans to proof of concept
● Looking for engagement with scientists and inventors
● Seek engagement with drug discovery units and therapeutic areas
● Be critical
Source: Gordon Wong, personal communication 2012.
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gether with the academic inventor. Here three components
are essential: in an open and transparent atmosphere, the
pharmaceutical company offers support to the academic in-
stitution to generate, if not already done, their (academic
side!) IP. This should be a unidirectional support from the
pharmaceutical company to the academic inventor as a
trust-building exercise. This approach of ‘the helping hand’
is not the normal current practice, which might be the rea-
son why a trust building within this early part of a relation-
ship is currently not the easiest way forward. On the other
hand, if the project is successful and positive for both sides,
then a later licence option already mentioned as the first
right of refusal will generate a joined vision for success shar-
ing on both sides.
Secondly, in the following discussions, the scope, dur-
ation and risk profile of a possible collaboration should
be developed. This exercise creates the joint project pro-
posal which defines the collaboration by framing, work-
ing tasks, milestones and risks benefits proposal. Within
this phase also includes the future phases, in case of col-
laboration success as well as failure scenarios, which
should be transparently addressed. The basic different
components for this building relationship are depicted
in Figure 3.
If this process is successful, the academic innovator
should go out of this phase with the spirit of ‘feeling well
supported’, ‘having a partner’ and ‘seeing further than be-
fore’. The pharmaceutical partner see the spirit as ‘we
are a partner in this project’, ‘let us work on this
innovation opportunity’.
Thereby, an important aspect is the ‘buy-in’ process of
internal stakeholders in both organisations. Buy-in by
both partnering organisations is also a supportive factor
for a strong relationship building process.Translate innovation into the value chain
To find the right opportunity is an easy sentence with a
difficult translation. From the pharmaceutical perspective
of pharmaceutical companies, the aim to find the right
opportunity and to open the right door is dependent on
the corporate strategy. A strong focus on the existing stra-
tegic (small molecular entities, also called smols, biologics,
therapeutics and diagnostics) and/or therapeutic areas will
automatically lead to narrowing the window of innovation
hunting. The opportunities found in these more narrow
windows are easier to find, select, develop and translate
into the own organisation of the pharmaceutical company
because of the closeness of the idea towards the receiving
organisation and the scientific expertise. Compared to
this, innovation outside the ‘comfort zone’ bears a higher
risk for scientific error and emotional (not invented here,
NIH syndrome) or resource challenges to get acceptance
within the organisation. After a certain amount of time
exposed to a certain company culture and a constantly
high work load, focusing on the own area of project inter-
ests can lead to a ‘not invented here’ syndrome. This may
lead to a negative bias against innovation coming from
the outside of the company zone into its own company.
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15 years to come into product reality need a long breath
and a constant internal ‘branding and advertising’ before
they might get accepted within the receiving organisation.
For example, innovation hunters within the Takeda organ-
isation should work on innovation, which are ‘far adjacen-
cies’ (see Figure 4; PG, personal communication, 2012) to
fulfil the strategic focus of the New Frontier Science
approach. These innovation hunters should have a special
social and communication skills set as depicted in Table 2.
To build this critical bridge, social skills like networking
building capability are essentially important.
Conclusions
The healthcare industry needs a boost of innovative ideas
coming from the academic institutions to overcome the
current challenges. New ways of collaborations and closer
connectivity between the basic research in academic and
the applied research within the pharmaceutical industry
are essential for a joint success. To build in this broader
context, a respectful and trustful relationship between the
partners is the key for a win-win situation between aca-
demic institutions and pharmaceutical companies.
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